The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib

YILMAZ A., ŞİMŞEK M., HANNARİCİ Z., Buyukbayram M. E., BİLİCİ M., Tekin S. B.

FUTURE ONCOLOGY, vol.17, pp.4545-4559, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17
  • Publication Date: 2021
  • Doi Number: 10.2217/fon-2021-0457
  • Journal Name: FUTURE ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.4545-4559
  • Keywords: glucose, hepatocellular carcinoma, lymphocyte, prognosis, sorafenib, survival, DIABETES-MELLITUS, PREDICTS SURVIVAL, CANCER, INFLAMMATION, PROGNOSIS, IMPACT, LEVEL, THERAPY, SCORE
  • Bezmialem Vakıf University Affiliated: Yes


Aim: To show the prognostic significance of the glucose-to-lymphocyte ratio (GLR) in hepatocellular carcinoma (HCC). Patients & methods: A total of 150 patients with advanced HCC who were treated with sorafenib in our center between January 2011 and December 2019 were included in the study retrospectively. Neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index and GLR were analyzed to assess their prognostic value using Kaplan-Meier and Cox regression analysis before and after propensity score matching (PSM). Results: In univariate analysis before and after PSM, albumin-bilirubin grade, neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, prognostic nutritional index, AFP level and GLR were found to be significantly associated with both progression-free and overall survival. In multivariate analysis before and after PSM, GLR, albumin-bilirubin grade and AFP were determined to be independent prognostic factors for progression-free and overall survival. Conclusion: The GLR prior to sorafenib treatment is a new prognostic biomarker that may predict survival in advanced HCC.